| Literature DB >> 30517365 |
Samanta Bárbara Vieira de Oliveira1, Soraya Coelho Costa Barroso1, Maria Aparecida Camargos Bicalho1,2, Adriano Max Moreira Reis3.
Abstract
OBJECTIVE: To determine the profile of medications used for self-medication by the elderly.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30517365 PMCID: PMC6276811 DOI: 10.31744/einstein_journal/2018AO4372
Source DB: PubMed Journal: Einstein (Sao Paulo) ISSN: 1679-4508
Clinical, functional and medication-use-related characteristics of the elderly participants
| Variable | n (%) |
|---|---|
| Self-medication | |
| Yes | 137 (80.6) |
| No | 33 (19.4) |
| Drug interaction* | |
| Yes | 94 (68.6) |
| No | 43 (31.4) |
| Therapeutic duplicity including self-medication* | |
| Yes | 78 (56.9) |
| No | 59 (43.1) |
| Self-medication with drugs included in the Beers list 2015* | |
| Yes | 76 (55.5) |
| No | 61 (44.5) |
| Self-medication with prescription drugs* | |
| Yes | 50 (36.5) |
| No | 87 (63.5) |
| Basic ADL* | |
| Independent | 145 (87.9) |
| Dependent | 20 (12.1) |
| Instrumental ADL* | |
| Independent | 65 (39.4) |
| Dependent | 100 (60.6) |
| Cognition* | |
| Not preserved | 85 (51.5) |
| Preserved | 80 (48.5) |
| Polypharmacy | |
| Yes | 165 (97.1) |
| No | 5 (2.9) |
* The total varied according to the ignored information. AVD: Activities of Daily Living.
Distribution of self-medicated drugs used by the elderly patients according to level 3 of the Anatomical Therapeutic Chemical classification system
| Anatomical Therapeutic Chemical Classification | n (%) |
|---|---|
| 1. Musculoskeletal system | 96 (36.1) |
| M03B – Central-acting muscle relaxants: dipyrone + orphenadrine + caffeine, caffeine + carisoprodol + diclofenac + paracetamol | 57 (21.4) |
| M01A – Non-steroid anti-inflammatory and antirheumatic agents: diclofenac, phenylbutazone, ibuprofen, nimesulide, glucosamine sulfate + sodium chondroitin sulfate, meloxicam, lornoxicam | 39 (14.7) |
| 2. Nervous system | 94 (35.3) |
| N02B – Other analgesics and antipyretics: dipyrone, paracetamol | 83 (31.2) |
| N06B – Psychostimulants: dipyrone + caffeine + isometheptene | 5 (1.9) |
| N07C – Antivertigo preparations: flunarizine | 4 (1.5) |
| N02A – Opioids: tramadol + paracetamol | 2 (0.8) |
| 3. Digestive tract and metabolism | 34 (12.8) |
| A02A – Antacids: sodium bicarbonate, magnesium hydroxide | 7 (2.6) |
| A02B – Drugs for peptic ulcer and gastroesophageal reflux disease: omeprazole, cimetidine | 6 (2.3) |
| A06A – Drugs for constipation: sodium picosulphate + | 5 (1.9) |
| A11A – Multivitamins, associations: vitamin complexes | 5 (1.9) |
| A12A – Calcium | 3 (1.1) |
| A03B – Belladonna e derivatives: scopolamine butylbromide | 3 (1.1) |
| A07D – Antipropulsives: loperamide | 2 (0.8) |
| A12C – Other mineral supplements | 1 (0.4) |
| A03D – Antispasmodics in combination with analgesics | 1 (0.4) |
| A11D – Vitamin B1 | 1 (0.4) |
| 4. Respiratory system | 8 (3.8 |
| R05C – Expectorants, except for combinations with cough suppressors: ambroxol | 1 (0.4) |
| R06A – Antihistamines of systemic use: buclizine, loratadine, promethazine, dexchlorpheniramine, paracetamol + chlorpheniramine + phenylephrine | 7 (2.6) |
| 5. Blood and blood forming organs | 6 (2.3) |
| B01A – Antithrombotic agents: acetylsalicylic acid | 5 (1.9) |
| B03A – Iron preparations: ferrous sulphate | 1 (0.4) |
| 6. Cardiovascular system | 6 (2.3) |
| C10A – Lipid modifying agents: omega 3 | 2 (0.8) |
| C03A – Low-ceiling diuretics, thiazides: hydrochlorothiazide | 1 (0.4) |
| C03D – Potassium sparing agents: spironolactone | 1 (0.4) |
| C09A – Inhibitors of angiotensin-converting enzyme: captopril | 1 (0.4) |
| C09C – Angiotensin II antagonists: losartan | 1 (0.4) |
| 7. Dermatological drugs | 2 (0.8) |
| D06A – Antibiotic for topical use: mupirocin | 1 (0.4) |
| D07A – Corticoids: dexamethasone | 1 (0.4) |
| 8. Anti-infectives for systemic use | 2 (0.8) |
| J01X – Other antibacterial agents: acriflavine hydrochloride + methenamine + methylthioninium chloride + | 1 (0.4) |
| J02A – Antimycotics for systemic use: ketoconazole | 1 (0.4) |
| 9. Genitourinary system and sex hormones | 1 (0.4) |
| G04B – Urinary system: sildenafil | 1 (0.4) |
| 10. Systemic hormonal drugs, except for sex hormones and insulins | 1 (0.4) |
| H02A – Systemic corticoids: prednisone | 1 (0.4) |
| Drugs not included on the ATC list | 16 (6.0) |
| Total | 266 (100) |
ATC: Anatomical Therapeutic Chemical.
Drug interaction with absolute frequency above 5
| Interaction | Severity | Clinical effect and action mechanism | n |
|---|---|---|---|
| ASA + dipyrone | Severe | Reduces ASA effectiveness by attenuating its antiplatelet effect | 48 |
| ASA + diclofenac | Severe | Increases risk of bleeding due to the additive effect on homeostasis | 12 |
| HCTZ + diclofenac | Severe | Reduces diuretic effects and may cause nephrotoxicity by reducing the production of renal prostaglandins | 9 |
| ASA + ibuprofen | Severe | Reduces ASA antiplatelet effect by competing for the COX-1 binding site and increases risk of bleeding by additive effect | 8 |
| Losartan + diclofenac | Moderate | Alters renal functions and/or increases BP by additive effect in the renal function and/or reduced the production of renal prostaglandins | 8 |
| Ibuprofen + diclofenac | Severe | Increases risk of bleeding by additive effect on homeostasis | 7 |
| ASA + nimesulide | Severe | Increases risk of bleeding by additive effect on homeostasis | 6 |
| Fluoxetine + diclofenac | Severe | Increases risk of bleeding by depleting the serotonin of platelets and by additive effect | 6 |
| Furosemide + ibuprofen | Severe | Reduces diuretic effectiveness and may cause nephrotoxicity by reducing the production of renal prostaglandins | 6 |
| Paracetamol + warfarin | Moderate | Increases risk of bleeding by inhibiting warfarin metabolism, or interfering in the formation of clotting factors | 6 |
| Furosemide + diclofenac | Severe | Reduces diuretic effectiveness and may cause nephrotoxicity by reducing the production of renal prostaglandins | 6 |
| HCTZ + nimesulide | Severe | Reduces diuretic effectiveness and may cause nephrotoxicity by reducing the production of renal prostaglandins | 6 |
| Enalapril + diclofenac | Severe | Alters renal functions and/or increases BP by additive effect on renal function and/or reduces the production of renal prostaglandins | 6 |
ASA: acetylsalicylic acid; HCTZ: Hydrochlorothiazide; COX-1: cyclooxygenase 1; BP: blood pressure.